Carmustine

Generic Name
Carmustine
Brand Names
Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
Drug Type
Small Molecule
Chemical Formula
C5H9Cl2N3O2
CAS Number
154-93-8
Unique Ingredient Identifier
U68WG3173Y
Background

A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index,...

Indication

For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.

Associated Conditions
Astrocytoma, Brain Stem Gliomas, Ependymoma, High Grade Glioma: Glioblastoma (GBM), Medulloblastomas, Metastatic Brain Tumors, Mycosis Fungoides (MF), Newly Diagnosed High-Grade Glioma, Recurrent Glioblastoma Multiforme (GBM), Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma, Refractory Non-Hodgkin's lymphoma
Associated Therapies
-
Clinical Trials
Related News

NovoTTF-100A With Bevacizumab and Carmustine in Treating Patients With Glioblastoma Multiforme in First Relapse

First Posted Date
2015-01-28
Last Posted Date
2018-01-09
Lead Sponsor
University of California, Davis
Registration Number
NCT02348255
Locations
🇺🇸

University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

🇺🇸

Piedmont Hospital, Atlanta, Georgia, United States

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

First Posted Date
2015-01-22
Last Posted Date
2018-11-20
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT02343666
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Yttrium Y 90 Basiliximab and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Mature T-cell Non-Hodgkin Lymphoma

First Posted Date
2015-01-21
Last Posted Date
2024-03-19
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
20
Registration Number
NCT02342782
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

First Posted Date
2014-12-31
Last Posted Date
2024-07-29
Lead Sponsor
International Extranodal Lymphoma Study Group (IELSG)
Target Recruit Count
76
Registration Number
NCT02329080
Locations
🇮🇹

IRST Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy

🇮🇹

Villa Sofia - Cervello, Palermo, Italy

🇨🇿

Facultni nemocnice, Brno, Czechia

and more 33 locations

Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma

First Posted Date
2014-02-11
Last Posted Date
2021-02-21
Lead Sponsor
Weill Medical College of Cornell University
Target Recruit Count
34
Registration Number
NCT02059239
Locations
🇺🇸

Weill Cornell Medical College, New York, New York, United States

Study of Melphalan HCl for Injection (Propylene Glycol-free), Carmustine, Etoposide, Cytarabine (BEAM Regimen) and Autologous Stem Cell Transplantation for Lymphoma

First Posted Date
2013-10-25
Last Posted Date
2018-02-13
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
50
Registration Number
NCT01969435
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Radiolabeled Monoclonal Antibody and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With High-Risk Lymphoid Malignancies

First Posted Date
2013-08-13
Last Posted Date
2020-08-04
Lead Sponsor
Fred Hutchinson Cancer Center
Target Recruit Count
20
Registration Number
NCT01921387
Locations
🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma

First Posted Date
2013-04-25
Last Posted Date
2024-05-29
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Target Recruit Count
17
Registration Number
NCT01840566
Locations
🇺🇸

Memorial Sloan Kettering Commack (Limited protocol activities), Commack, New York, United States

🇺🇸

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 4 locations

Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma

First Posted Date
2013-01-17
Last Posted Date
2015-05-07
Lead Sponsor
Fred Hutchinson Cancer Center
Registration Number
NCT01769911
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease

First Posted Date
2012-10-10
Last Posted Date
2018-12-19
Lead Sponsor
Baylor College of Medicine
Target Recruit Count
75
Registration Number
NCT01702961
Locations
🇺🇸

The Methodist Hospital, Houston, Texas, United States

🇺🇸

Texas Children's Hospital, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy